Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) EBIT Margin (2023)

Contineum Therapeutics has reported EBIT Margin over the past 1 years, most recently at 77.87% for Q2 2023.

  • Quarterly results put EBIT Margin at 77.87% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 22.52% (changed N/A YoY), and the annual figure for FY2023 was 32.15%, changed.
  • EBIT Margin for Q2 2023 was 77.87% at Contineum Therapeutics, down from 5559.78% in the prior quarter.
  • Over the last five years, EBIT Margin for CTNM hit a ceiling of 5559.78% in Q1 2023 and a floor of 77.87% in Q2 2023.